Every 8-K that Niagen Bioscience, Inc (NAGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NAGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAGE filings page.
Niagen Bioscience, Inc. reported second‑quarter 2026 results with net sales of $29.8 million versus $31.1 million a year earlier. Gross margin was 64.8%. The company generated net income of $1.0 million, diluted EPS of $0.01, and Adjusted EBITDA of $3.0 million. For the first six months of 2026 it produced $1.6 million of operating cash flow and ended June 30, 2026 with $66.7 million in cash and cash equivalents, having repurchased $2.8 million of common stock in the quarter.
Tru Niagen® remained the core driver with $24.2 million of Q2 2026 net sales, while direct‑to‑consumer website revenue grew 23% year over year. The company launched the Niagen Plus telehealth platform and at‑home injection kit, obtained LegitScript certification, and added Olympia Pharmaceuticals as a 503B compounding partner. Niagen introduced NB4168, an oral small‑molecule candidate for Ataxia‑Telangiectasia that received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations, engaged Evotec for preclinical and IND‑enabling work, rebranded its external research program, and appointed Abhijit Kale, Ph.D., to lead global external research. Management expects 2026 e‑commerce growth of 10–15% and characterizes 2026 as a year of strategic investment with higher operating expenses but continued focus on positive operating cash flow.
Niagen Bioscience, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected all eight director nominees, including Frank L. Jaksch, Jr., Robert Fried, Steven Rubin, Wendy Yu, Gary Ng, Kristin Patrick, Ann Cohen, and Hamed Shahbazi.
Stockholders also ratified the appointment of Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 56,152,066 votes for and 2,256,090 against. In addition, they approved, on an advisory basis, the compensation of the company’s named executive officers.
Niagen Bioscience, Inc. reported first-quarter 2026 net sales of $31.5 million, up 3% year-over-year, with Tru Niagen® contributing $22.4 million. Gross margin was 63.5%, reflecting a favorable business mix.
Net income was $6.3 million, helped by a $4.8 million gain on the divestiture of the Analytical Reference Standards and Services operating segment, while adjusted EBITDA was $3.8 million. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Cash and cash equivalents totaled $66.5 million with no outstanding borrowings, after using $1.2 million in operating cash flow and repurchasing $2.4 million of common stock.
The company reaffirmed its 2026 outlook for net sales to increase 10–15% year-over-year, excluding the divested segment, and expects slightly higher gross margin. It plans higher sales and marketing and research and development spending, while general and administrative expense is now projected to rise by $3–$4 million.
Niagen Bioscience, Inc. announced that its Board of Directors has doubled the company’s share repurchase authorization to $20 million of outstanding common stock, up from the previously approved $10 million program.
Through March 17, 2026, Niagen Bioscience has repurchased approximately $2.6 million of its common stock under this program. The repurchase authorization runs through October 31, 2027, unless earlier completed, suspended, modified, or terminated by the Board. Repurchases may occur from time to time via open market purchases, privately negotiated transactions, or trading plans, and the company is not obligated to repurchase any specific amount.
Niagen Bioscience, Inc. reported strong growth for 2025, with net sales rising 30% to $129.4 million and gross margin improving 250 basis points to 64.3%. Net income more than doubled to $17.4 million, or $0.22 basic EPS, and Adjusted EBITDA increased to $20.4 million.
The company ended 2025 with $64.8 million in cash and no outstanding borrowings, supported by $13.5 million of operating cash flow. Tru Niagen and Niagen ingredient sales grew 27% and 45%, respectively, and 2026 guidance calls for 10–15% net sales growth and slightly higher margins as it invests in marketing, R&D, and infrastructure.
Niagen Bioscience, Inc. is reshaping its business by selling substantially all assets of its analytical reference standards and services unit, operated through ChromaDex, Inc. and ChromaDex Analytics, Inc., to VHG Labs, part of LGC Group, in an all-cash transaction that closed on February 24, 2026. The divestiture is described as part of a broader strategy to exit non-core activities so the company can concentrate on its NAD+ science platform, intellectual property, and commercial growth initiatives in healthy aging and longevity. Niagen will also provide certain operational and administrative transition services to the buyer for up to six months after closing in exchange for service fees recognized as the services are performed.
Niagen Bioscience, Inc. reported that its subsidiary ChromaDex, Inc. entered into a new assignment agreement with Queen’s University Belfast, effective December 16, 2025, replacing prior joint ownership and license arrangements. QUB assigned all of its rights in certain patent assets to ChromaDex and released the company from royalty, payment, accounting, and related obligations under the former agreements, including royalties accrued through 2025. In return, ChromaDex will make a one-time payment of approximately $1,000,000 for accrued royalties through 2024, annual payments of $500,000 and £35,000 from 2026 to 2038, and additional one-time payments of $1,500,000 in 2035 and $2,000,000 in 2038. The agreement includes customary representations, warranties, and indemnities, and the company disclosed that it issued a related press release.
Niagen Bioscience (NAGE) approved a share repurchase program authorizing up to $10.0 million of common stock. Purchases may occur in open market or privately negotiated transactions, or under a trading plan adopted in the future, in accordance with applicable securities laws.
The authorization expires on October 31, 2027 and can be modified, suspended, or terminated at any time at the Board’s discretion. The program does not obligate the company to buy any specific amount of shares.
Niagen Bioscience, Inc. furnished an 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025, and posted a corporate presentation on its website.
The press release is included as Exhibit 99.1 and the presentation as Exhibit 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed “filed” under the Exchange Act.
Niagen Bioscience, Inc. disclosed in a Current Report on Form 8-K that on October 6, 2025 it issued a press release announcing an increase to its financial outlook for the full year ending December 31, 2025. The company states the press release is furnished as Exhibit 99.1 and clarifies this information is being furnished, not filed, under the Exchange Act so it is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated. No specific revenue, earnings, or guidance figures are included in the filing text provided.
Niagen Bioscience (Nasdaq:NAGE) filed a Form 8-K detailing the outcomes of its 24 June 2025 Annual Meeting.
- 2017 Equity Incentive Plan: share reserve increased by 4,750,000 shares.
- New ESPP: 650,000 shares available; purchase price set at 85% of the lower of the offering- or purchase-date close.
- All eight directors re-elected; Crowe LLP ratified as auditor.
- Advisory say-on-pay passed (54,899,483 for / 1,160,619 against).
The amended plan (Ex. 10.1) and ESPP (Ex. 10.2) were filed; no other material changes were disclosed.